The prognostic effect of brain natriuretic peptide levels on outcomes of hospitalized patients with COVID-19

Yazan Abdeen; Ahmad Kaako; Mohammad Alnabulsi; Amira Okeh; William Meng; Richard Miller

doi:10.4103/ajm.ajm_169_20

Avicenna Journal of Medicine, Table of Contents

CC BY-NC-ND 4.0 · Avicenna J Med 2021; 11(01): 20-26
DOI: 10.4103/ajm.ajm_169_20

Original Article

The prognostic effect of brain natriuretic peptide levels on outcomes of hospitalized patients with COVID-19

Authors

Yazan Abdeen

Pulmonary and Sleep Physicians of Houston, PA
Ahmad Kaako

Mercy Hospital Fort Smith, Fort Smith, AR
Mohammad Alnabulsi

Saint Michael’s Medical Center, Newark, NJ
Amira Okeh

University of Illinois at Chicago, Chicago, IL, USA
William Meng

Mercy Hospital Fort Smith, Fort Smith, AR
Richard Miller

Mercy Hospital Fort Smith, Fort Smith, AR

Subject Editor:

Abstract

Natriuretic peptides are biomarkers of myocardial stress and are frequently elevated among patients with severe respiratory illnesses, typically in the absence of elevated cardiac-filling pressures or clinical heart failure. Elevation of brain natriuretic peptide (BNP) or NT-proBNP is associated with worse outcomes among patients with Acute Respiratory Distress Syndrome (ARDS). We conducted a retrospective cohort study based on a comprehensive review of Electronic Medical Records (EMRs) of patients with Coronavirus Disease 2019 (COVID-19) to evaluate whether BNP on admission has prognostic value on mortality and hospital length of stay (LOS) among patients admitted with confirmed COVID-19 along with the inclusion of additional prognostic variables. Overall, 146 patients were included after analyzing 230 patients’ EMR and excluding potential confounding factors for abnormal BNP. Our statistical analysis did not show a statistically significant association between BNP level and mortality rate (P = 0.722) or ICU LOS ( P = 0.741). A remarkable secondary outcome to our study was that impaired renal function (GFR<60) on admission was significantly associated with an increased mortality rate (P = 0.026) and an increased ICU LOS (P = 0.022). Although various studies have presented the predictive role of pro-BNP among patients with respiratory distress in the past years, our study did not find BNP to be an accurate predictive and prognostic factor among patients with COVID-19 in our study population. Renal impairment and high Acute Physiology and Chronic Health Evaluation (APACHE) II scores on admission, on the other hand, have demonstrated to be strong predictors for COVID-19 morbidity and mortality. This study could represent an introduction to more prominent multicenter studies to evaluate additional prognostic factors and minimize the ordering of nonspecific testing.

Keywords

Brain natriuretic peptide - COVID-19 - SARS-CoV-2

Full Text

References

References
1 Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med 2020; 382: e102
2 Schuchat A CDC Covid-19 Response Team. Public health response to the initiation and spread of pandemic COVID-19 in the United States, February 24–April 21, 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 551-6
3 Gandhi RT, Lynch JB, Del Rio C. Mild or moderate Covid-19. N Engl J Med 2020; 383: 1757-66
4 Henry B, De Oliveira M, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (Covid-19): A meta-analysis. Clin Chem Lab Med 2020; 58: 1021-8
5 Wendel Garcia PD, Fumeaux T, Guerci P, Heuberger DM, Montomoli J, Roche-Campo F. et al. Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with COVID-19 in Europe: Initial report of the international RISC-19-ICU prospective observational cohort. EClinicalMedicine 2020; 25: 100449
6 Ibrahim NE, Januzzi Jr JL. Established and emerging roles of biomarkers in heart failure. Circ Res 2018; 123: 614-29
7 Bajwa EK, Januzzi JL, Gong MN, Thompson BT, Christiani DC. Prognostic value of plasma N-terminal probrain natriuretic peptide levels in the acute respiratory distress syndrome. Crit Care Med 2008; 36: 2322-7
8 Sekulic A, Trpkovic S, Pavlovic A, Marinkovic O, Ilic A. Scoring systems in assessing survival of critically ill ICU patients. Med Sci Monit: Int Med J Exp Clin Res 2015; 21: 2621-9
9 SFAR. Scoring systems for ICU and surgical patients. Available from: https://sfar.org/scores2/apache22.php#haut [Last accessed on 2020 Dec 3]
10 Vallabhajosyula S, Wang Z, Murad M, Vallabhajosyula S, Sundaragiri PR, Kashani K. et al. Natriuretic peptides to predict short-term mortality in patients with sepsis: A systematic review and meta-analysis. Mayo Clin Proc Innov Qual Outcomes 2020; 4: 50-64
11 Gao L, Jiang D, Wen X, Cheng X, Sun M, He B. et al. Prognostic value of NT-proBNP in patients with severe COVID-19. Respir Res 2020; 21: 83
12 Ferreira F, Bota D, Bross A, Mélot C, Vincent J. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA 2001; 286: 1754-8
13 Abdeen Y, Sen P, Safdar S, Katapally R, Arqoob AA, Macbruce D. et al. The usefulness of brain natriuretic peptide level in diagnosis and prognosis of patients admitted to critical care unit with shortness of breath. J Emerg Trauma Shock 2015; 8: 205-9
14 Palaiodimos L, Chamorro-Pareja N, Karamanis D, Li W, Zavras PD, Mathias P. et al. Diabetes is associated with increased risk for in-hospital mortality in patients with COVID-19: A systematic review and meta-analysis comprising 18,506 patients. Hormones 2020; 1-10
15 Palaiodimos L, Kokkinidis DG, Li W, Karamanis D, Ognibene J, Arora S. et al. Severe obesity is associated with higher in-hospital mortality in a cohort of patients with COVID-19 in the Bronx, New York. Metabolism 2020; 108: 154262
16 Wang L, He W, Yu X, Hu D, Bao M, Liu H. et al. Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up. J Infect 2020; 80: 639-45
17 Guo T, Fan Y, Chen M, Wu X, Zhang L, He T. et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020; 5: 811-8
18 Morrison L, Harrison A, Krishnaswamy P, Kazanegra R, Clopton P, Maisel A. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol 2002; 39: 202-9
19 Davis M, Espiner E, Richards G, Billings J, Town I, Neill A. et al. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet 1994; 343: 440-4
20 Shor R, Rozenman Y, Bolshinsky A, Harpaz D, Tilis Y, Matas Z. et al. BNP in septic patients without systolic myocardial dysfunction. Eur J Intern Med 2006; 17: 536-40
21 Noritoshi N, Toshio N, Masaaki U, Toru S, Shingo K, Fumio S. et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000; 102: 865-70
22 Casserly B, Klinger J. Brain natriuretic peptide in pulmonary arterial hypertension: Biomarker and potential therapeutic agent. Drug Des, Devel Ther 2009; 3: 269-87
23 Holmes S, Espiner E, Richards A, Yandle T, Frampton C. Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab 1993; 76: 91-6
24 McCullough P, Duc P, Omland T, McCord J, Nowak R, Hollander J. et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: An analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis 2003; 41: 571-9
25 Takami Y, Horio T, Iwashima Y, Takiuchi S, Kamide K, Yoshihara F. et al. Diagnostic and prognostic value of plasma brain natriuretic peptide in non-dialysis-dependent CRF. Am J Kidney Dis 2004; 44: 420-8
26 Naganuma T, Sugimura K, Wada S, Yasumoto R, Sugimura T, Masuda C. et al. The prognostic role of brain natriuretic peptides in hemodialysis patients. Am J Nephrol 2002; 22: 437-44
27 Sise ME, Baggett MV, Shepard JO, Stevens JS, Rhee EP. Case 17-2020: A 68-year-old man with covid-19 and acute kidney injury. N Engl J Med 2020; 382: 2147-56
28 Chu KH, Tsang WK, Tang CS, Lam MF, Lai FM, To KF. et al. Acute renal impairment in coronavirus-associated severe acute respiratory syndrome. Kidney Int 2005; 67: 698-705
29 Jung J, Park B, Hong S, Koh Y, Suh G, Jeon K. et al. Acute kidney injury in critically ill patients with pandemic influenza a pneumonia 2009 in Korea: A multicenter study. J Crit Care 2011; 26: 577-85
30 Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L. et al. Kidney disease is associated with in-hospital death of patients with covid-19. Kidney Int 2020; 97: 829-38
31 Diao B, Wang C, Wang R, Feng Z, Tan Y, Wang H. et al. Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.2020 [Preprint]
32 Su H, Yang M, Wan C, Yi LX, Tang F, Zhu HY. et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int 2020; 98: 219-27